Abstract:Objective To explore the potential value of patient characteristics in predicting overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel plus prednisone.Methods We retrospectively analyzed the data of 115 consecutive Chinese patients with mCRPC received docetaxel chemotherapy in our institution from Nov.2005 to Sep 2011.The median age at diagnosis was 65 years old and median serum prostate-specific antigen (PSA) level at diagnosis was 100.0 μg/L.The Gleason score≤7 in 26 patients and ≥8 in 89 patients.The median age at chemotherapy was 68 years old,ranging from 51 to 82 years old.The median baseline PSA level was 90.5 μg/L,ranging from 0.8 to 4066.4 μg/L.The median baseline hemoglobin (Hb) concentration was 121 g/L and median baseline alkaline phosphatase (ALP) concentration was 110 U/L.The time to castration resistance ranged from 2 to 114 months and the median value was 23.All 115 patients have bone metastasis,and 16 cases were simultaneously observed the presence of visceral metastasis including lung (9 cases),bladder (4 cases),liver (2 cases) and brain (1 case).The average cycles of chemotherapy was 6,ranging from 1 to 16.We retrospectively collected the variables including patient characteristics at diagnosis and characteristics before the chemotherapy.All laboratory analyses were performed in the same laboratory.Survival analysis was performed using KaplanMeier curves,and the differences in overall survival rates were assessed using the log-rank test.Only variables that were statistically significant in the univariate analysis (P＜0.05) were included in the multivariate model.Results The follow-up was performed until April 30,2012,and median follow-up time was 45 months,ranging from 2 to 74 months.During the follow-up period,87 of 115 patients (75.7％) died and the median OS for the entire cohort was 17 months,ranging from 2 to 46 months.The univariate analysis identified a total of 8 statistically significant predictors of OS:baseline serum PSA level,baseline Hb concentration,baseline ALP concentration,baseline lactate dehydrogenase (LDH) concentration,baseline gamma-glutamyl transpeptidase (GGT) concentration,ECOG PS,time to castration resistance and cycles of chemotherapy.Subsequent multivariate analysis reserved baseline ALP≥110 U/L,baseline Hb＜110 g/L,time to castration resistance＜23 months and cycles of chemotherapy＜6 as independent prognostic factors for shorter OS.Conclusions This retrospective analysis has demonstrated that baseline ALP concentration,baseline Hb concentration,time to castration resistance and cycles of chemotherapy could provide independent prognostic information of OS in Chinese patients with mCRPC treated with docetaxel plus prednisone.

A Multicenter, Randomized Clinical Trial Comparing The Three-Weekly Docetaxel Regimen Plus Prednisone Versus Mitoxantone Plus Prednisone For Chinese Patients With Metastatic Castration Refractory Prostate Cancer

Characteristics Of Chinese Patients With Advanced Prostate Cancer: A Muliticentre, Non-Interventional, Observational, Prospective, Registry Study Of Docetaxel.

Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer after Docetaxel Failure: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Bridging Study

Docetaxel Plus Prednisone Versus Mitoxantrone Plus Prednisone for Metastatic Hormone-Refractory Prostate Cancer in Chinese Patients: Experience of a Single Center

[Docetaxel Plus Prednisone Versus Mitoxantrone Plus Prednisone As First-Line Chemotherapy for Metastatic Hormone-Refractory Prostate Cancer: Long-Term Effects and Safety].

A multicenter observational study of the real-world use of docetaxel for metastatic castration-resistant prostate cancer in China.

Clinical activity of abiraterone plus prednisone in docetaxel-naοve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer.

Efficacy and safety of molecular targeted agents combined with docetaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: A Meta-analysis

Real-world Use of Docetaxel for Metastatic Castration-Resistant Prostate Cancer in China: Results from a Large Observational Study

Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel Plus Prednisone

Docetaxel plus prednisone for treatment of hormone refractory prostate cancer

[Clinical Efficacy of Docetaxel Combined with Carboplatin in Patients with Metastatic Castration-Resistant Prostate Cancer].

[Predictor analysis of PSA response of docetaxel combined with prednisone in the treatment of metastatic castration resistant prostate cancer].

Clinical Results of Mitoxantrone Plus Prednisone in Hormone Refractory Prostate Cancer

Efficacy and Prognostic Factors of Abiraterone Combined with Prednisone Treating Metastatic Castration-Resistant Prostate Cancer Patients

Neoadjuvant Dose-Modified Docetaxel in Squamous Cell Carcinoma of the Head and Neck: A Phase 3 Study

Docetaxel Chemotherapy Plus Androgen-Deprivation Therapy in High-Volume Disease Metastatic Hormone-Sensitive Prostate Cancer in Chinese Patients: an Efficacy and Safety Analysis

[Paclitaxel liposome for the treatment of castration-resistant prostate cancer]

Efficacy and Toxicity of Molecular Targeted Therapies in Combination with Docetaxel for Metastatic Castration-Resistant Prostate Cancer: a Meta-Analysis of Phase III Randomized Controlled Trials

Prognosic Analysis of Chemotherapy for Patients with Castration Resistant Prostate Cancer

Comparing efficacy of first-line treatment of metastatic castration resistant prostate cancer: a network meta-analysis of randomized controlled trials